133 related articles for article (PubMed ID: 23820134)
21. [Gastrointestinal stromal tumor of small intestine associated with lymph node metastasis: a report of 2 cases with review of literatures].
Kong M; Wang YL; Xu LJ; Teng XD
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):617-20. PubMed ID: 20079191
[TBL] [Abstract][Full Text] [Related]
22. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH
Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947
[TBL] [Abstract][Full Text] [Related]
23. Imatinib responsiveness in canine mast cell tumors carrying novel mutations of c-KIT exon 11.
Nakano Y; Kobayashi T; Oshima F; Fukazawa E; Yamagami T; Shiraishi Y; Takanosu M
J Vet Med Sci; 2014 Apr; 76(4):545-8. PubMed ID: 24292246
[TBL] [Abstract][Full Text] [Related]
24. Ex vivo evaluation of imatinib mesylate for induction of cell death on canine neoplastic mast cells with mutations in c-Kit exon 11 via apoptosis.
Rossi G; Bertani C; Mari S; Marini C; Renzoni G; Ogilvie G; Magi GE
Vet Res Commun; 2013 Jun; 37(2):101-8. PubMed ID: 23315207
[TBL] [Abstract][Full Text] [Related]
25. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
[TBL] [Abstract][Full Text] [Related]
26. Resected duodenal gastrointestinal stromal tumour with an affected margin and exon 9 mutation: adjuvant therapy.
Salas NR; Cubillo A
Anticancer Drugs; 2012 Jun; 23 Suppl():S18-21. PubMed ID: 22713591
[TBL] [Abstract][Full Text] [Related]
27. [KIT mutation analysis in pathological diagnosis and target-therapy of gastrointestinal stromal tumors: an update].
Chen LR
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):440-3. PubMed ID: 17845754
[No Abstract] [Full Text] [Related]
28. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
[TBL] [Abstract][Full Text] [Related]
29. [Effect of c-kit mutation on the prognosis of gastrointestinal stromal tumors: a meta-analysis].
Zhao WY; Cao H; Zhang Y; Shen ZY; Wu ZY
Zhonghua Wai Ke Za Zhi; 2009 Jun; 47(11):857-62. PubMed ID: 19961019
[TBL] [Abstract][Full Text] [Related]
30. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
31. Rectal gastrointestinal stromal tumors associated with a novel germline KIT mutation.
Woźniak A; Rutkowski P; Sciot R; Ruka W; Michej W; Debiec-Rychter M
Int J Cancer; 2008 May; 122(9):2160-4. PubMed ID: 18183595
[TBL] [Abstract][Full Text] [Related]
32. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
[TBL] [Abstract][Full Text] [Related]
33. Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour.
Grabellus F; Ebeling P; Worm K; Sheu SY; Antoch G; Frilling A; Schmid KW
Gut; 2007 Jul; 56(7):1025-6. PubMed ID: 17566038
[No Abstract] [Full Text] [Related]
34. Gastrointestinal stromal tumors (GISTs): a pathology view point.
Sornmayura P
J Med Assoc Thai; 2009 Jan; 92(1):124-35. PubMed ID: 19260254
[TBL] [Abstract][Full Text] [Related]
35. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.
Haller F; Detken S; Schulten HJ; Happel N; Gunawan B; Kuhlgatz J; Füzesi L
Ann Surg Oncol; 2007 Feb; 14(2):526-32. PubMed ID: 17139461
[TBL] [Abstract][Full Text] [Related]
36. KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors.
Corless CL; McGreevey L; Town A; Schroeder A; Bainbridge T; Harrell P; Fletcher JA; Heinrich MC
J Mol Diagn; 2004 Nov; 6(4):366-70. PubMed ID: 15507676
[TBL] [Abstract][Full Text] [Related]
37. Complete response in a melanoma patient treated with imatinib.
Brown MC; Casasola RJ
J Laryngol Otol; 2012 Jun; 126(6):638-40. PubMed ID: 22643209
[TBL] [Abstract][Full Text] [Related]
38. KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors.
De Giorgi U
J Clin Oncol; 2007 Mar; 25(9):1146-7; author reply 1147-8. PubMed ID: 17369583
[No Abstract] [Full Text] [Related]
39. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
[TBL] [Abstract][Full Text] [Related]
40. Gastrointestinal stromal tumor presenting as a rectovaginal mass. Clinicopathologic and molecular-genetic characterization of a rare tumor with a literature review.
Pelz AF; Agaimy A; Daniels M; Evert M; Schulz HU; Lüders P; Müller G; Lasota J; Röpke A; Wieacker P; Miettinen M; Schneider-Stock R
Hum Pathol; 2011 Apr; 42(4):586-93. PubMed ID: 21237497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
